FFF Enterprises: BioSupply Trends Newsletter
Monday, June 19, 2017

BCG Vaccine Could Permanently Reverse Type 1 Diabetes

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Results of a new clinical trial show that the bacillus Calmette-Guerin (BCG) vaccine could permanently reverse advanced type 1 diabetes in mice, as well as help to restore proper immune response to insulin-producing beta cells.
[ read more ]

New Study Supports CDC Recommendation for Two-Dose HPV Vaccine in Children

A new study conducted at the Boston Medical Center is the first to support new recommendations by the Centers for Disease Control and Prevention (CDC) for a two-dose HPV vaccine to prevent genital warts in kids under 15 years old.
[ read more ]

AHA Updates Kawasaki Disease Diagnosis and Management Guidelines

The American Heart Association (AHA) has made its first update to the diagnosis and management guidelines of Kawasaki disease issued in 2004, which integrate new findings on its epidemiology, genetics, pathogenesis and long-term outcomes.
[ read more ]

Industry News

 
 

From CSL Behring

The U.S. Food and Drug Administration has accepted CSL Behring’s biologics license application for Privigen (immune globulin intravenous [human] 10% liquid) to treat neuromuscular disability and impairment and for maintenance therapy to prevent relapse in patients with chronic inflammatory demyelinating polyneuropathy. [ read more ]

From Octapharma USA

The U.S. Food and Drug Administration has granted Octapharma USA orphan drug designation for Octagam (immune globulin intravenous [human] 10% liquid) for treatment of dermatomyositis.  [ read more ]

From Novo Nordisk

The U.S. Food and Drug Administration has approved Novo Nordisk’s Rebinyn (coagulation factor IX [recombinant], glycopegylated) for the treatment of hemophilia B in adults and children. [ read more ]

IVIG & Albumin Supply Index

 
 

What's New at FFF

METHOTREXATE (Accord Healthcare)

METHOTREXATE (injection) is indicated in the management of selected adults with severe, active rheumatoid arthritis, or children with active polyarticular-course juvenile rheumatoid arthritis who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy, including full-dose nonsteroidal anti-inflammatory agents. It is supplied in a single-dose 25 mg/mL vial.

For more information about METHOTREXATE, login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective April 1, 2017, through June 30, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $65.28 $64.23
Flebogamma J1572 $60.35 $59.38
Gammagard S/D J1566 $65.28 $64.23
Gammaplex J1557 $83.23 $81.90
Octagam J1568 $72.17 $71.02
Privigen J1459 $77.73 $76.49
SCIG
CUVITRU ** J3490/J3590/J7799 - -
Hizentra J1559 $98.26 $96.68
HyQvia J1575 $129.56 $127.48
IVIG / SCIG
Gammagard Liquid J1569 $80.86 $79.57
Gammaked J1561 $67.86 $66.77
Gamunex-C J1561 $67.86 $66.77

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** Cuvitru does not yet have Medicare rates.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.